Ivaltinostat formic (C09-1140-573)

Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formicAppearance:OilIC50& Target:HDACIn Vitro:Ivaltinostat (CG-200745; 0.01-100 μM; 48 hours) formic inhibits growth of prostate cancer cells (LNCaP, DU145 and PC3 cells). Ivaltinostat (1, 10 μM; 24, 48 hours) formic increases sub-G1 population, and activates caspase-9, -3 and -8. Ivaltinostat (In Vivo:Ivaltinostat (CG-200745; p.o.; 30mg/kg/day; for 7 days) formic attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys. MCE has not independently confirmed the accuracy of these methods. They are for reference onlyBiological Activity:Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic. Specification: 0.99 Molecular Formula: C25H35N3O6 Molecular Weight: 473.56